Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A potential survival benefit in coronary artery bypass grafting with micro-axial temporary pump recovery in patients with reduced left ventricular ejection fraction.

Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs·2026
Same author

Ten Guiding Principles for the Management of Postcardiotomy Cardiogenic Shock: Salvaging the Unsalvageable.

The Annals of thoracic surgery·2026
Same author

Clinical course and outcomes of antibody-mediated rejection after heart transplant in the contemporary era.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Donor heart injury caused by liver needle biopsy during multi-organ procurement surgery: A case report.

World journal of transplantation·2026
Same author

Impact of kidney ischemic time on two-year survival and graft outcomes after simultaneous heart-kidney transplantation: Analysis of the OPTN registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Impact of donor mechanism of injury on donation after circulatory death heart transplant outcomes: An analysis of the UNOS National Registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Related Experiment Video

Updated: May 10, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K

Surgically implanted endovascular, microaxial left ventricular assist device: A single institution study.

Erin M Schumer1, Yun Zhu Bai1, Kunal D Kotkar1

  • 1Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, Mo.

JTCVS Techniques
|February 14, 2024
PubMed
Summary

The Impella 5.5 left ventricular assist device shows variable outcomes based on patient selection. Further research is needed to optimize its use in cardiac support.

Keywords:
cardiogenic shocktemporary mechanical circulatory supportventricular assist device

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K

Related Experiment Videos

Last Updated: May 10, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K

Area of Science:

  • Cardiology
  • Medical Devices
  • Mechanical Circulatory Support

Background:

  • The Impella 5.5 is a widely used microaxial left ventricular assist device.
  • Over 10,000 Impella 5.5 devices have been implanted globally.
  • This study details a significant single-center experience with the Impella 5.5.

Purpose of the Study:

  • To describe the outcomes of a large cohort of patients treated with the Impella 5.5.
  • To analyze the device's performance across different clinical indications.
  • To evaluate the safety and efficacy of the Impella 5.5 in various cardiac conditions.

Main Methods:

  • Retrospective analysis of 126 patients who received the Impella 5.5 from May 2020 to December 2022.
  • Patients were categorized into five groups based on the intended use of the Impella 5.5.
  • Data collected included demographics, operative details, and postoperative outcomes.

Main Results:

  • Overall survival to device explant was 76.2%, with 67.5% survival to discharge.
  • Midterm survival at a median follow-up of 318 days was 60.3%.
  • Survival at a median of 650 days was 60.3%.

Conclusions:

  • Outcomes with the Impella 5.5 vary significantly depending on the specific indication for use.
  • Careful patient selection is crucial for successful Impella 5.5 implantation.
  • Additional clinical experience is necessary to refine patient selection criteria and maximize benefits.